53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications

Key Takeaways Explain This Topic AI

Type 1 diabetes results from autoimmune, T-cell-mediated destruction of pancreatic beta cells; diagnostic confirmation utilizes an islet autoantibody panel including anti-glutamic acid decarboxylase 65 (anti-GAD65), anti-insulinoma-associated antigen-2 (anti-IA-2), and anti-zinc transporter 8 (anti-ZnT8); Latent Autoimmune Diabetes in Adults (LADA) presents after age 30 with slow beta-cell failure, positive anti-GAD65, and low C-peptide.

Intensive basal-bolus therapy calculates a Total Daily Dose (TDD) of 0.4 to 0.6 units/kg/day in newly diagnosed non-honeymoon patients, divided 50% basal (ultra-long-acting degludec or glargine) and 50% prandial/bolus (rapid-acting lispro, aspart, or glulisine) distributed across 3 meals.

Precision mealtime dosing requires calculating two core parameters: the Insulin-to-Carbohydrate Ratio (ICR = 500 / TDD, defining grams of carbohydrate covered by 1 unit of insulin) and the Insulin Sensitivity Factor / Correction Factor (ISF = 1800 / TDD, defining the mg/dL glucose decrease per 1 unit of rapid-acting insulin).

Continuous Glucose Monitoring (CGM) clinical targets require Time in Range (TIR: 70-180 mg/dL) >70%, Time Below Range (TBR: <70 mg/dL) <4%, severe hypoglycemia (<54 mg/dL) <1%, and a glycemic coefficient of variation (%CV) <=36%; Automated Insulin Delivery (AID) systems combine CGM with predictive algorithms to modulate insulin delivery.

Morning fasting hyperglycemia requires distinguishing the Dawn Phenomenon (counter-regulatory surge of GH and cortisol between 4-8 AM; 3 AM glucose is elevated or normal; managed by increasing bedtime basal insulin) from the Somogyi Effect (rebound hyperglycemia following 2-3 AM nocturnal hypoglycemia; 3 AM glucose is low; managed by reducing bedtime basal insulin or providing an evening snack).

Last updated: October 2026

Immunopathogenesis & Diagnostic Autoantibody Profiling in T1D

Type 1 diabetes mellitus (T1D) is a chronic autoimmune disorder characterized by targeted immune-mediated destruction of insulin-producing beta cells in the islets of Langerhans within the pancreas. This culminates in absolute insulin deficiency, obligating lifelong exogenous insulin replacement to sustain cellular metabolism and prevent fatal ketoacidosis.

Cellular & Genetic Pathogenesis

T-Cell-Mediated Insulitis : Autoreactive CD4+ T-helper 1 (Th1) cells and CD8+ cytotoxic T lymphocytes infiltrate the pancreatic islets, releasing proinflammatory cytokines (interferon-gamma, tumor necrosis factor-alpha, interleukin-1-beta) and inducing perforin/granzyme- and Fas/FasL-mediated apoptosis of beta cells. Pancreatic alpha (glucagon-secreting) and delta (somatostatin-secreting) cells are characteristically spared.

Genetic Susceptibility : Strongest association resides within the Human Leukocyte Antigen (HLA) class II locus on chromosome 6p21, specifically the HLA-DR3-DQ2 (DRB1 0301-DQB1 0201) and HLA-DR4-DQ8 (DRB1 0401-DQB1 0302) haplotypes. Individuals heterozygous for both DR3-DQ2 and DR4-DQ8 carry the highest genetic risk (~20-fold increased susceptibility).

The Islet Autoantibody Panel

While circulating autoantibodies do not directly mediate beta-cell destruction, they serve as critical, highly specific serological biomarkers of autoimmune insulitis: SEROLOGICAL AUTOANTIBODY PROFILES IN TYPE 1 DIABETES

• Autoantibody Target Abbreviation Clinical Sensitivity & Diagnostic Utility
• ═════════════════════════════════════════════════════════════════════════════════════════════════════

Glutamic Acid anti-GAD65 • Present in 70-80% of newly diagnosed patients.

Decarboxylase 65 • Most persistent autoantibody; remains detectable for years/decades.

• Gold-standard serological marker for LADA in adults.

Islet Antigen-2 anti-IA-2 • Present in 50-70% of pediatric and adolescent onsets.

(Tyrosine Phosphatase) (ICA512) • Correlates strongly with rapid, aggressive beta-cell destruction.

Zinc Transporter 8 anti-ZnT8 • Highly specific to the insulin secretory granule membrane.

• Present in 60-70% of new onsets; fills diagnostic gaps when GAD65 is negative.

Islet Cell Cytoplasmic ICA • Immunofluorescence assay detecting intracellular cytoplasmic antigens.

Antibodies • Historical standard; widely replaced by recombinant GAD/IA-2/ZnT8 assays.

Insulin Autoantibodies IAA • Most prevalent initial autoantibody in infants and young children (<5 years).

• In adults, sensitivity is low (<20-30%).

• Must be drawn before or within 1 to 2 weeks of exogenous insulin therapy!

• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• The Three Staged Progression of Type 1 Diabetes

Stage 1 (Presymptomatic Autoimmunity) : Presence of >=2 islet autoantibodies ; normoglycemia (normal FPG, OGTT, and HbA1c); asymptomatic. Lifetime progression to clinical diabetes approaches 100%.

Stage 2 (Presymptomatic Dysglycemia) : Presence of >=2 islet autoantibodies with emerging dysglycemia (FPG 100-125 mg/dL, 2-h OGTT 140-199 mg/dL, or HbA1c 5.7%-6.4%); asymptomatic. (Note: In 2022, the FDA approved Teplizumab , an anti-CD3 monoclonal antibody, administered as a 14-day IV infusion to delay the onset of Stage 3 clinical diabetes by a median of 2 to 3 years in Stage 2 patients aged >=8 years).

Stage 3 (Overt Clinical Disease) : Autoantibodies present with symptomatic hyperglycemia fulfilling standard diagnostic criteria (polyuria, polydipsia, weight loss, or diabetic ketoacidosis).

Latent Autoimmune Diabetes in Adults (LADA: 'Type 1.5')

LADA represents a slowly progressive subtype of autoimmune diabetes presenting in adulthood. Diagnostic criteria include:

Age of onset >=30 to 35 years .

Presence of circulating islet autoantibodies (predominantly anti-GAD65 in >90% of cases).

Lack of requirement for exogenous insulin for at least the first 6 months following diagnosis.

Clinical Trap : Patients with LADA are routinely misdiagnosed with type 2 diabetes due to their older age at onset. However, they typically possess a normal or lean BMI (<25 kg/m2), lack phenotypic features of metabolic syndrome (no severe hypertension, hypertriglyceridemia, or acanthosis nigricans), and experience rapid secondary failure of oral antidiabetic agents (sulfonylureas, metformin) within 12 to 24 months. Laboratory testing confirms a low or declining fasting C-peptide (<0.6 ng/mL or <0.2 nmol/L) . Sulfonylureas must be avoided because they accelerate beta-cell exhaustion; early introduction of basal-bolus insulin preserves residual endogenous C-peptide and prevents ketoacidosis.

Intensive Basal-Bolus Insulin Therapy Architecture

Intensive insulin therapy strives to emulate normal human pancreatic physiology: continuous, low-level basal insulin secretion to suppress hepatic gluconeogenesis and lipolysis around the clock, interspersed with rapid bursts of prandial insulin to match mealtime carbohydrate absorption.

Total Daily Dose (TDD) Estimation & Distribution

In a metabolically stable patient with newly diagnosed type 1 diabetes outside the 'honeymoon phase':

Starting TDD Formula : 0.4 to 0.6 units/kg/day of total insulin.

During the transient 'honeymoon phase' (temporary recovery of residual beta-cell secretion occurring weeks to months after diagnosis), requirements may fall to 0.2 to 0.4 units/kg/day.

During acute illness, systemic corticosteroid therapy, or adolescent pubertal growth spurts, requirements often rise to 0.8 to 1.2+ units/kg/day.

The 50/50 Rule :

50% of TDD administered as Basal Insulin (once or twice daily).

50% of TDD administered as Prandial Bolus Insulin , divided across three meals (approximately 15% to 20% of TDD per meal). STARTING TDD ESTIMATION (EXAMPLE: 70-KG ADULT)

• Parameter Calculation & Clinical Dose Allocation
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Estimated Total Daily Dose (TDD) 70 kg x 0.5 units/kg/day = 35 units total / day

Basal Component (50% of TDD) 35 units x 0.50 = 17.5 units ──► 18 units Basal (e.g., Degludec)

• Prandial Component (50% of TDD) 35 units x 0.50 = 17.5 units ──► 17 units Prandial (divided over 3 meals)
• Breakfast: 6 units rapid-acting analog (e.g., Lispro)
• Lunch: 5 units rapid-acting analog
• Dinner: 6 units rapid-acting analog
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Basal Insulin Formulations Comparison PHARMACOKINETICS OF BASAL INSULIN FORMULATIONS

• Formulation Trade Name Onset Peak Duration Biochemical Mechanism & Pearls
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Degludec Tresiba 30-90 min None > 42 hours • Forms soluble multi-hexamers in SC depot.

(U-100, U-200) (Flat) • Half-life ~25 hr; ultra-flat profile.

• Lowest rate of nocturnal hypoglycemia.

• Flexible dosing time (>= 8 hr apart).

Glargine U-300 Toujeo 6 hours None 36 hours • Forms a compact, dense subcutaneous depot.

(Flat) • Slower release and flatter curve than U-100.

Glargine U-100 Lantus, 1-2 hours None 20-24 hours • Formulated at pH 4.0; micro-precipitates

Basaglar, (Flat) at physiological tissue pH 7.4.

Semglee • DO NOT MIX in same syringe with other insulins!

Detemir Levemir 1-2 hours Minimal 14-20 hours • Binds interstitial and serum albumin via

(6-8 hr) myristic acid fatty acid side chain.

• Frequently requires twice-daily (BID) dosing.

NPH (Neutral Humulin N, 1-3 hours 4-10 hours 12-18 hours • Protamine crystalline suspension.

Protamine Hagedorn) Novolin N • Marked nocturnal hypoglycemia risk if given

at dinner; MUST dose at bedtime (21:00-22:00).

• ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
• Prandial Insulin Formulations Comparison

Rapid-Acting Analogs (Lispro [Humalog], Aspart [Novolog], Glulisine [Apidra]) :

Onset: 10 to 15 minutes; Peak: 1 to 2 hours; Duration: 3 to 5 hours.

Amino acid substitutions prevent insulin hexamers from associating, allowing immediate monomeric dissociation and capillary absorption.

Administered 0 to 15 minutes before meals (or immediately after meals in toddlers or patients with unpredictable food intake).

Ultra-Rapid Analogs (Faster Aspart [Fiasp], Faster Lispro [Lyumjev]) :

Onset: 2 to 5 minutes; Peak: 45 to 60 minutes; Duration: 3 to 4 hours.

Formulated with excipients (niacinamide or treprostinil/citrate) that accelerate microvascular permeability and local absorption.

Inhaled Human Insulin (Afrezza) :

Dry powder formulation inhaled at mealtime. Peak action within 12 minutes; duration 1.5 to 3 hours.

Requires baseline spirometry (FEV1); strictly contraindicated in asthma, COPD, and active smokers due to acute bronchospasm risk.

Regular (Crystalline) Human Insulin (Humulin R, Novolin R) :

Onset: 30 to 60 minutes; Peak: 2 to 4 hours; Duration: 6 to 8 hours.

Must be injected 30 to 45 minutes prior to meal ingestion. Mismatches physiological carbohydrate absorption curves, predisposing to early postprandial hyperglycemia followed by late postprandial (3-5 hours) hypoglycemia .

Precision Advanced Dosing Formulas: The Rules of 500 and 1800

Optimal postprandial glycemic control in type 1 diabetes requires dynamic mealtime dosing that accounts for both dietary carbohydrate intake and pre-meal glycemic excursions.

1. Insulin-to-Carbohydrate Ratio (ICR: The Rule of 500)

The ICR defines how many grams of carbohydrate are metabolized by 1 unit of rapid-acting insulin: ICR = 500 TDD ( grams of carbohydrate per 1 unit of insulin ) \text{ICR} = \frac{500}{\text{TDD}} \quad (\text{grams of carbohydrate per 1 unit of insulin}) ICR = TDD 500 ​ ( grams of carbohydrate per 1 unit of insulin ) Carbohydrate Coverage Dose (units) = Total Grams of Carbohydrate in Meal ICR \text{Carbohydrate Coverage Dose (units)} = \frac{\text{Total Grams of Carbohydrate in Meal}}{\text{ICR}} Carbohydrate Coverage Dose (units) = ICR Total Grams of Carbohydrate in Meal ​

2. Insulin Sensitivity Factor / Correction Factor (ISF: The Rule of 1800)

The ISF defines the anticipated drop in blood glucose (in mg/dL) achieved by 1 unit of rapid-acting insulin: ISF = 1800 TDD ( mg/dL reduction in blood glucose per 1 unit of insulin ) \text{ISF} = \frac{1800}{\text{TDD}} \quad (\text{mg/dL reduction in blood glucose per 1 unit of insulin}) ISF = TDD 1800 ​ ( mg/dL reduction in blood glucose per 1 unit of insulin ) Correction Dose (units) = Current Blood Glucose − Target Blood Glucose ISF \text{Correction Dose (units)} = \frac{\text{Current Blood Glucose} - \text{Target Blood Glucose}}{\text{ISF}} Correction Dose (units) = ISF Current Blood Glucose − Target Blood Glucose ​

3. Total Mealtime Prandial Bolus Equation Total Prandial Bolus = Carbohydrate Coverage Dose + Correction Dose \text{Total Prandial Bolus} = \text{Carbohydrate Coverage Dose} + \text{Correction Dose} Total Prandial Bolus = Carbohydrate Coverage Dose + Correction Dose Total Prandial Bolus = ( Meal Carbohydrates (g) ICR ) + ( Current Glucose − Target Glucose ISF ) \text{Total Prandial Bolus} = \left( \frac{\text{Meal Carbohydrates (g)}}{\text{ICR}} \right) + \left( \frac{\text{Current Glucose} - \text{Target Glucose}}{\text{ISF}} \right) Total Prandial Bolus = ( ICR Meal Carbohydrates (g) ​ ) + ( ISF Current Glucose − Target Glucose ​ )

Tip

CLINICAL PEARL: INSULIN ON BOARD (IOB) Rapid-acting insulin analogs possess an active duration of 3 to 4 hours. If a patient administers a correction bolus for hyperglycemia and checks their blood glucose 1 to 2 hours later, considerable unabsorbed insulin remains active in subcutaneous tissue (Insulin on Board). Administering another correction bolus before 3 to 4 hours have elapsed causes 'insulin stacking' , the leading cause of severe postprandial hypoglycemia in intensive insulin therapy.

Continuous Glucose Monitoring (CGM) & Automated Insulin Delivery

Continuous Glucose Monitoring (CGM) utilizes subcutaneous transcutaneous enzymatic sensors (measuring interstitial glucose every 1 to 5 minutes) and has revolutionized outpatient glycemic surveillance, superseding intermittent capillary fingerstick blood glucose monitoring. STANDARDIZED CGM AMBULATORY GLUCOSE PROFILE (AGP) TARGETS

(Consensus targets for non-pregnant adults with T1D / T2D)

• CGM Metric Target Range Target Percentage Clinical Significance
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Time in Range (TIR) 70 to 180 mg/dL > 70% of readings • Each 10% increase in TIR reduces

(3.9-10.0 mmol/L) (> 16 hr 48 min/day) retinopathy & microalbuminuria risk by ~40%.

Time Below Range (TBR Level 1) 54 to 69 mg/dL < 4% of readings • Alert zone for hypoglycemia avoidance.

(3.0-3.8 mmol/L) (< 1 hour/day)

Time Below Range (TBR Level 2) < 54 mg/dL < 1% of readings • Clinically significant, dangerous hypoglycemia

(Severe Hypoglycemia) (< 3.0 mmol/L) (< 15 minutes/day) mandating immediate regimen de-escalation.

Time Above Range (TAR Level 1) 181 to 250 mg/dL < 25% of readings • Identifies postprandial excursions.

(10.1-13.9 mmol/L) (< 6 hours/day)

Time Above Range (TAR Level 2) > 250 mg/dL < 5% of readings • Severe hyperglycemia; ketone check trigger.

(> 13.9 mmol/L) (< 1 hr 12 min/day)

Glycemic Variability (%CV) %CV = (SD / Mean) <= 36% • Target <= 36% defines stable control;

x 100 %CV > 36% reflects erratic glycemic excursions.

Glucose Management Calculated from Matches HbA1c • Mathematical estimation of laboratory HbA1c

Indicator (GMI) mean sensor glucose derived from >= 14 days of CGM sensor data.

• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Automated Insulin Delivery (AID) Systems ('Artificial Pancreas')

AID systems combine a continuous subcutaneous insulin infusion (CSII) pump, a real-time CGM sensor, and an advanced algorithmic control loop (proportional-integral-derivative or model predictive control):

Predictive Low-Glucose Suspend (PLGS) : Algorithmic prediction of hypoglycemia 30 minutes in advance automatically attenuates or suspends basal insulin delivery, virtually eliminating nocturnal severe hypoglycemia.

Automated Basal & Micro-Bolus Delivery : Algorithmic increases in basal rates and automated micro-boluses counteract rising glucose levels.

Hybrid Closed-Loop : The user must still announce meals and manually input carbohydrate grams to deliver prandial boluses; basal adjustments and correction boluses are automated.

Unraveling Morning Hyperglycemia: Dawn Phenomenon vs. Somogyi Effect

A classic clinical conundrum is the patient with type 1 diabetes who awakens with marked fasting morning hyperglycemia (e.g., 220 to 280 mg/dL). Two diametrically opposed pathophysiological mechanisms produce this presentation: DAWN PHENOMENON VS. SOMOGYI EFFECT DIFFERENTIATION

• Feature Dawn Phenomenon Somogyi Effect (Rebound Hyperglycemia)
• ═════════════════════════════════════════════════════════════════════════════════════════════════════════
• Primary Mechanism Circadian nocturnal surge of Rebound hyperglycemia triggered by unrecognized
• counter-regulatory hormones (GH, nocturnal hypoglycemia; acute surge of epinephrine,
• cortisol, glucagon, epinephrine) glucagon, and cortisol drives intense hepatic

between 04:00 and 08:00 AM. glycogenolysis and gluconeogenesis.

• 03:00 AM Blood Glucose ELEVATED or NORMAL LOW / HYPOGLYCEMIC
• (Key Diagnostic Pivot!) (>= 100 to 140 mg/dL) (< 70 mg/dL, often 40-60 mg/dL)

Nocturnal Symptoms None; patient sleeps soundly Nightmares, nocturnal diaphoresis, night sweats,

waking with headache or tachycardia.

• Definitive Management INCREASE bedtime basal insulin dose, DECREASE evening or bedtime basal insulin dose,
• switch to ultra-long-acting analog, or provide a bedtime snack combining complex

or increase 04:00-08:00 pump rate. carbohydrates and protein (peanut butter/cheese).

═════════════════════════════════════════════════════════════════════════════════════════════════════════

Caution

THE BOARD TRAP: NEVER ADJUST MORNING DOSES FOR MORNING NUMBERS When faced with morning fasting hyperglycemia, the catastrophic error is empirically increasing the bedtime basal insulin without checking the 03:00 AM blood glucose. If the patient has the Somogyi effect, increasing bedtime insulin deepens the 03:00 AM nocturnal hypoglycemia, which can induce fatal nocturnal hypoglycemic seizures or severe cardiac arrhythmias ('dead-in-bed syndrome'). Always obtain 03:00 AM readings before changing evening regimens.

Outpatient DKA Prevention & Sick-Day Management Protocol

Diabetic Ketoacidosis (DKA) is a life-threatening acute metabolic emergency characterized by the biochemical triad of hyperglycemia (blood glucose ≥200 mg/dL or known diabetes), ketonemia/ketonuria (beta-hydroxybutyrate >3.0 mmol/L), and high anion gap metabolic acidosis (arterial pH <7.30, serum bicarbonate <18 mEq/L, anion gap >12 mEq/L).

Outpatient Sick-Day Education Rules

Infections (gastroenteritis, influenza, pneumonia, UTI) induce an intense surge of counter-regulatory stress hormones (cortisol, epinephrine, glucagon), promoting severe insulin resistance and lipolysis. Patient sick-day rules include:

NEVER Stop Basal Insulin : The cardinal rule of type 1 diabetes. Even if the patient is nauseated, anorexic, or actively vomiting and consuming zero calories, basal insulin must NEVER be omitted . Basal insulin is required to shut off adipose lipolysis and hepatic ketogenesis, not just to handle food. Withholding insulin because 'I am not eating' is the primary trigger of hospital-admitted DKA.

Frequent Glucose Monitoring : Check capillary glucose (or monitor CGM) every 2 to 4 hours around the clock.

Urine or Blood Ketone Testing : Test ketones every 2 to 4 hours whenever blood glucose is >250 mg/dL , or regardless of glucose level if the patient experiences nausea, vomiting, or abdominal pain.

Blood beta-hydroxybutyrate meters are vastly superior to urine acetoacetate dipsticks (which can yield false-negative results in early DKA or false-positive results with dehydration).

Beta-hydroxybutyrate <0.6 mmol/L: Normal.

0.6 to 1.5 mmol/L: Impending ketosis; requires supplemental insulin and hydration.

1.5 to 3.0 mmol/L: High risk of DKA; contact physician immediately.

3.0 mmol/L: Severe DKA; requires immediate emergency department transport.

Aggressive Hydration : Consume at least 8 to 12 ounces (240-350 mL) of fluid per hour . If glucose is >200 mg/dL, consume calorie-free fluids (water, broth). If glucose drops <200 mg/dL due to poor food intake, switch to carbohydrate-containing fluids (sports drinks, diluted fruit juice) to maintain glucose between 150-200 mg/dL so that scheduled and supplemental insulin can continue to be administered safely.

Supplemental Correction Boluses : Administer rapid-acting insulin every 2 to 4 hours using the ISF. If moderate-to-large ketones are present, increase the calculated correction bolus by 10% to 20% of the patient's Total Daily Dose (TDD) .

Emergency Department Referral Red Flags :

Persistent vomiting for >4 to 6 hours with complete inability to retain oral fluids.

Large ketones that fail to improve after two consecutive supplemental insulin correction doses.

Development of rapid, deep breathing ( Kussmaul respirations ), acetone-scented breath, or severe abdominal pain.

Lethargy, confusion, or altered mental status.

Loading diagram... Morning Hyperglycemia Differential Diagnostic Algorithm